Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

New analysis examines RAP-219’s effect during the first month of treatment and consistency of efficacy over the treatment period, effectiveness across baseline disease severities, and impact on seizure severityBOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorder ...